What is the market's earnings forecast for Axsome Therapeutics next quarter?

What is Axsome Therapeutics's gross profit margin?

What does Axsome Therapeutics do and what are its main business segments?

What is the revenue and EPS growth rate for Axsome Therapeutics year over year?

What is Axsome Therapeutics's latest dividend and current dividend yield?

What were the key takeaways from Axsome Therapeutics’s earnings call?

Did Axsome Therapeutics beat or miss consensus estimates last quarter?

What were the key takeaways from Axsome Therapeutics's earnings call?

- **Revenue Growth**: Q4 2025 revenue up 65% YoY to $196 million, driven by AUVELITY ($507 million, +74%), SUNOSI, and SYMBRAVO launch.
- **Pipeline Momentum**: AUVELITY sNDA for Alzheimer's agitation (PDUFA April 30), AXS-12 narcolepsy NDA imminent, and AXS-17 epilepsy Phase II prep underway.
- **Commercial Expansion**: AUVELITY sales force tripled to 600 reps; SYMBRAVO targeting 52% payer coverage.
- **Financial Efficiency**: Net loss down 61% YoY to $28.6 million; cash balance $323 million for operational sustainability.
- **Strategic Differentiation**: AXS-05's rapid onset and safety profile position it for leadership in MDD and ADA markets.

**【CEO Summary Section】**
- Total revenue for Q4 2025: $196 million (65% YoY growth); Full year revenue: $639 million (66% YoY growth). Key drivers: AUVELITY ($507 million, 74% YoY), SUNOSI ($124.8 million, 32% YoY), and SYMBRAVO launch.
- Pipeline highlights: sNDA for AUVELITY in Alzheimer's disease agitation (PDUFA April 30), Phase II/III trial for AXS-05 in smoking cessation, and AXS-12 narcolepsy NDA submission imminently.
- Commercial expansion: AUVELITY sales force expanded to 600 reps; SYMBRAVO targeting headache specialists with 52% payer coverage.
- CNS innovation: AXS-17 (epilepsy) Phase II-enabling activities underway; solriamfetol expanded into ADHD, MDD, and binge eating disorder trials.

**【CFO Financial Commentary】**
- Q4 2025 net loss: $28.6 million (-61% YoY); Full year net loss: $183.2 million (-36% YoY). Key metrics: 
  - AUVELITY gross to net (GTN): High 40s% (Q4), expected mid-50s% in 2026.
  - R&D expenses: $183.3 million (2025), down 2% YoY due to completed trials.
  - SG&A: $570.6 million (2025), +39% YoY for commercial expansion.
  - Cash balance: $323 million (sufficient for operations into cash flow positivity).

**【Q&A Key Highlights】**
- **FDA Policy & Trials**: AXS-17 epilepsy development prioritized; ADHD trials split into pediatric/adolescent studies per FDA guidance.
- **AUVELITY ADA Launch**: 70%+ scripts expected in Medicare Part D (favorable GTN); launch readiness by Q2 2026.
- **SYMBRAVO Market Access**: 52% payer coverage; GPO contracts secured for 2026 negotiations.
- **AXS-17 Epilepsy**: Preclinical success in seizure models; Phase II target announcement in 2026.
- **Competitive Landscape**: AUVELITY's rapid onset and safety profile differentiate in MDD and ADA markets; no direct overlap with COBENFY psychosis indication.


Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 2025 revenue of $171 million (+63% YoY), driven by AUVELITY (+69% YoY), SUNOSI (+35% YoY), and SYMBRAVO launch.
- **Pipeline Momentum**: AXS-05 (Alzheimer's agitation) NDA submission, AXS-12 narcolepsy NDA expected in Q4, and AXS-14 fibromyalgia Phase III trial initiation.
- **Commercial Strength**: AUVELITY with 46,000 prescribers and 85% payer coverage, SYMBRAVO with 5,000+ prescriptions in first quarter.
- **Financial Health**: Net loss of $47.2 million (-28% YoY), $325 million cash, and plans for cash flow positivity.

**【CEO Summary Section】**
- Total revenue reached $171 million in Q3 2025, up 63% YoY, driven by strong performance across AUVELITY, SUNOSI, and SYMBRAVO.
- AUVELITY net product sales grew 69% YoY to $136.1 million, with 209,000 prescriptions (+46% YoY) and 46,000 unique prescribers.
- SUNOSI net product sales increased 35% YoY to $32.8 million, with 53,000 prescriptions (+12% YoY).
- SYMBRAVO generated $2.1 million in first-quarter sales, with over 5,000 prescriptions and 3,300 new patients.
- Pipeline highlights include AXS-05 (Alzheimer's agitation) NDA submission, AXS-12 narcolepsy NDA expected in Q4, and AXS-14 fibromyalgia Phase III launch by year-end.

**【CFO Financial Commentary】**
- Q3 net loss was $47.2 million (-28% YoY), with $325.3 million in cash, sufficient for operations and near-term growth.
- AUVELITY and SUNOSI gross-to-net (GTN) discounts were in the high 40% range, expected to rise to low 50% in Q4.
- R&D expenses decreased 11% YoY to $40.2 million, while SG&A rose 57% YoY to $150.2 million due to commercial expansion and SYMBRAVO launch.

**【Q&A Highlights】**
- **AUVELITY Primary Care Growth**: 1/3 of prescribers are primary care clinicians, with NBRx up 50% YoY and 85% payer coverage.
- **SYMBRAVO Launch Strategy**: Focused on 150 headache centers, 5,000+ prescriptions in Q3, and 52% payer coverage.
- **AXS-05 Alzheimer's Agitation**: Submission for NDA, targeting 70% of narcolepsy patients with cataplexy and poor tolerability to current treatments.
- **Pipeline Expansion**: 4 Phase III trials planned for Q4, including solriamfetol in ADHD and MDD with excessive sleepiness.
- **Cash Flow Positivity**: Management confident in achieving cash flow positivity with current $325 million cash balance and disciplined spending.

Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue of $150 million (+72% YoY) driven by Auvelity ($119.6M, +84%) and Sunosi ($30M, +35%).
- **New Product Launch**: SYMBRAVO generated $410K in first 2 weeks, with 38% coverage and strong early feedback.
- **Pipeline Milestones**: AXS-05 sNDA submission for Alzheimer's agitation this quarter; AXS-12 NDA for narcolepsy in Q4.
- **Financial Health**: $303M cash balance supports operations; net loss narrowed to $48M (-20% vs. Q1).

**【CEO Summary Section】**
- Total revenue for Q2 2025 was $150 million, up 72% year-over-year, driven by strong performance of Auvelity and Sunosi.
- Launched SYMBRAVO, a novel acute migraine treatment, in mid-June, generating $410,000 in net sales in its first partial quarter.
- Pipeline progress includes: 
  - AXS-05 sNDA submission for Alzheimer's disease agitation expected this quarter.
  - AXS-12 NDA submission for narcolepsy with cataplexy planned for Q4.
  - AXS-14 Phase III trial for fibromyalgia set to begin in Q4.
  - Solriamfetol Phase III trials in ADHD (pediatric) and MDD with excessive sleepiness scheduled for Q4.

**【CFO Financial Commentary】**
- Auvelity net sales: $119.6 million (84% YoY growth).
- Sunosi net sales: $30 million (35% YoY growth), including $1.1 million in royalties.
- Gross-to-Net (GTN) discounts: mid-50s for Auvelity and Sunosi; low-80s for SYMBRAVO.
- Net loss: $48 million ($0.97 per share), down from $59.4 million in Q1 and $79.3 million in Q2 2024.
- Cash balance: $303 million, sufficient for operations and cash flow positivity.

**【Q&A Key Highlights】**
- **Auvelity Payer Coverage**: Expanded to 83% of lives, including 73% commercial and 100% government. GTN maintained at mid-50s despite 28 million new covered lives.
- **SYMBRAVO Launch**: Early feedback positive; 38% coverage (26% commercial). GTN expected to remain high due to new patient starts.
- **AXS-12 Strategy**: Positioned as a rapid-acting alternative to orexin agonists, with Phase III data included in NDA.
- **ADHD Pipeline**: Solriamfetol pediatric trial design finalized; leveraging adult efficacy data for confidence in pediatric results.
- **Smoking Cessation**: AXS-05 Phase II/III trial expected Q4; component contribution studies required for FDA approval.
- **Competitive Dynamics**: Sunosi maintains 9% market share in EDS; AXS-12 expected to complement Sunosi in narcolepsy treatment.
- **Regulatory Updates**: AXS-05 sNDA submission on track; solriamfetol trials in MDD and shift work disorder progressing as planned.

Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript

- **62% Revenue Growth**: Q1 2025 total revenue $121.5M, driven by Auvelity (+80%) and Sunosi (+17%).
- **Pipeline Momentum**: 5 products across 6 indications by end-2026, including Symbravo launch June 2025.
- **AXS-05 Alzheimer's Agitation**: sNDA submission Q3 2025 with Breakthrough Therapy Designation.
- **Profitability Path**: $300.9M cash; targeting cash flow positivity with scaled infrastructure.
- **Symbravo Launch**: 100+ sales reps targeting neurology centers; unique CGRP mechanism.


**【CEO Opening Remarks】**
- Q1 2025 total revenue grew 62% YoY to $121.5M, driven by Auvelity (+80%) and Sunosi (+17%).
- FDA approved Symbravo, a novel migraine treatment, reflecting Axsome's internal R&D strength.
- Pipeline highlights:
  - AXS-14 (fibromyalgia) NDA submitted; 17M+ U.S. patients with unmet need.
  - AXS-05 (Alzheimer's agitation) sNDA expected Q3 2025; Breakthrough Therapy Designation.
  - AXS-12 (narcolepsy) NDA anticipated H2 2025; Phase III data shows rapid cataplexy relief.
- 2025 outlook: 5 marketed products across 6 indications by end-2026.

**【CFO Financial Review】**
- Q1 2025 key financials:
  - Total revenue: $121.5M (vs. $75M YoY)
  - Auvelity: $96.2M (vs. $53.4M YoY)
  - Sunosi: $25.2M (vs. $21.6M YoY)
  - GTN discounts: ~55% for both products, stable for remainder of year.
- Expenses:
  - R&D: $44.8M (vs. $36.8M YoY) due to Phase III trials and Symbravo launch prep.
  - SG&A: $120.8M (vs. $99M YoY) driven by commercial expansion.
- Net loss: $59.4M (-$1.22/share) vs. $68.4M (-$1.44/share) YoY.
- Cash: $300.9M as of Q1, sufficient for operations and cash flow positivity.

**【Commercial Update】**
- Auvelity:
  - Q1 TRx: 167K (+76% YoY, +5% QoQ)
  - 26K new patients, 50% first-line use, 78% payer coverage.
  - Sales force expanded to 450+ reps; DTC campaign launching later 2025.
- Sunosi:
  - Q1 TRx: 46K (+12% YoY)
  - 3.8K new patients, 83% payer coverage.
- Symbravo:
  - 100+ sales reps targeting acute migraine specialists.
  - Launching June 2025 with unique multi-mechanism CGRP approach.

**【Q&A Highlights】**
1. **AXS-05 Alzheimer's Agitation**:
   - FDA pre-NDA meeting reaffirmed data package; sNDA submission Q3 2025.
   - Breakthrough Therapy Designation; priority review possible post-filing.
2. **Symbravo Launch**:
   - Targeting 100+ neurology centers; payer coverage negotiations ongoing.
   - AHS meeting June 2025 for additional data presentations.
3. **Auvelity Generics**:
   - Teva 180-day exclusivity; no generics expected until 2039.
   - Sustained commercial momentum with 13+ years of exclusivity.
4. **Pipeline Expansion**:
   - AXS-14 (fibromyalgia) sales team expansion planned; 17M U.S. patients.
   - Solriamfetol Phase III in ADHD pediatric patients launching 2025.
5. **Profitability**:
   - Cash flow positivity expected; operating leverage from scaled infrastructure.
   - R&D/S&G investments focused on high ROI late-stage programs.


Axsome Therapeutics (AXSM)-5 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 2024 total product revenue $386 million (+88% YoY), driven by Auvelity (+124%) and Sunosi (+26%).
- **Pipeline Momentum**: 3 NDAs planned for 2025 (AXS-05, AXS-12, AXS-14) and 3 Phase III readouts in Q1.
- **Commercial Expansion**: 40 new Auvelity reps added; Symbravo launch targeting neurologists.
- **Financial Health**: $315 million cash balance; on track for cash flow positivity.


**【CEO Summary Section】**
- Axsome Therapeutics reported total net product revenue of $386 million for 2024, with high double-digit growth for Auvelity and Sunosi.
- Received U.S. approval for Symbravo, an oral acute migraine treatment, in January 2025.
- Pipeline includes 3 product candidates set for NDA submissions in 2025: AXS-05 (Alzheimer's agitation), AXS-12 (narcolepsy with cataplexy), and AXS-14 (fibromyalgia).
- Phase III trials for solriamfetol in ADHD, MDD, and other conditions are on track for Q1 2025 topline results.

**【CFO Financial Commentary】**
- Q4 2024 total product revenue: $118.8 million (66% YoY growth); Full Year 2024: $385.7 million (88% YoY growth).
- Auvelity net product sales: $92.6 million (Q4) / $291.4 million (FY) (+89%/+124% YoY).
- Sunosi net product revenue: $26.2 million (Q4) / $94.3 million (FY) (+16%/+26% YoY).
- R&D expenses: $55 million (Q4) / $187.1 million (FY) (+80%/+91% YoY).
- SG&A expenses: $113.3 million (Q4) / $411.4 million (FY) (+30%/+27% YoY).
- Net loss for FY 2024: $287.2 million, with $315 million cash balance.

**【Commercial Update】**
- Auvelity prescriptions: 158,000 (Q4) (+10% QoQ); Sunosi: 49,000 (Q4) (+4% QoQ).
- Auvelity sales force expanded by 40 reps (10-15% increase), targeting primary care providers.
- Symbravo launch planned for 2025, focusing on headache specialists and neurologists.

**【Q&A Highlights】**
- DTC promotions for Auvelity and Symbravo to begin in 2025, timed to patient flow seasons.
- AXS-05 and AXS-12 NDAs expected in H2 2025, with regulatory meetings pending.
- Solriamfetol Phase III trials in ADHD and MDD set for Q1 2025 readouts.
- Symbravo launch trajectory expected to mirror oral CGRP competitors, with targeted approach.


Actual										-0.88	-0.49	-0.61	-0.78	-0.78	-0.86	-0.93	-0.9	-1.03	-1.06	-1.07	-1.41	-0.26	-1.54	-1.32	-2.08	-1.44	-1.67	-1.34	-1.54	-1.22	-0.97	-0.94	-0.56
Forecast										-0.6244	-0.6156	-0.5718	-0.7521	-0.8189	-0.9191	-0.9538	-1.0215	-1.0027	-1.0061	-1.0501	-1.1259	-1.304	-1.2135	-1.2033	-1.1714	-1.2045	-1.3071	-1.3835	-1.001	-1.3512	-1.0551	-0.8612	-0.6925
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-40.94%	+20.40%	-6.68%	-3.71%	+4.75%	+6.43%	+2.50%	+11.89%	-2.72%	-5.36%	-1.90%	-25.23%	+80.06%	-26.91%	-9.70%	-77.57%	-19.55%	-27.76%	+3.14%	-53.85%	+9.71%	+8.07%	-9.15%	+19.13%

Actual	--	--	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	0	8.82M	16.85M	24.40M	94.58M	46.70M	57.79M	71.53M	75.00M	87.17M	103.74M	118.77M	121.46M	150.04M	170.99M	194.69M
Forecast	--	--	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	0	6.92M	16.64M	21.75M	25.47M	40.88M	54.87M	69.24M	73.29M	86.92M	98.37M	118.07M	119.16M	138.02M	162.67M	194.55M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+27.49%	+1.26%	+12.16%	+271.31%	+14.24%	+5.33%	+3.31%	+2.33%	+0.28%	+5.45%	+0.59%	+1.94%	+8.71%	+5.11%	+0.07%

AXSM

AXSM fundamentals

AXSM Q4 2025 Earnings

Earnings Call

You can ask Aime

AXSM

AXSM fundamentals

AXSM Q4 2025 Earnings

Earnings Call

AXSM Earnings Call Summary for Q4/20258:00 AM on Feb 23, 2026

AXSM Earnings Call Summary for Q3/20258:00 AM on Nov 3, 2025

AXSM Earnings Call Summary for Q2/20258:00 AM on Aug 4, 2025

AXSM Earnings Call Summary for Q1/20258:00 AM on May 5, 2025

AXSM Earnings Call Summary for Q4/20248:00 AM on Feb 18, 2025

You can ask Aime